The expansion enables the manufacture of its PEGtech range at commercial metric ton scale quantities in a cGMP environment. Dr. Reddy’s has eight API manufacturing facilities, six FDA-approved plants in India, one FDA-approved plant in Mexico, and one FDA-approved plant in Mirfield, UK.
Dr. R. Ananthanarayanan, president of the Pharmaceutical Services and Active Ingredients business of Dr. Reddy’s said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing.”